SARS-COV-2 and COVID-19 - A Randomized controlled trail (unblinded)

Phase 2

Not yet recruiting

Brief Summary: The purpose of the proposal of these Siddha trail medicines is to validate the therapeutic efficacy and safety profile to administer for the SARS-CoV-2 COVID-19 which has been more dreadful for the community and more challenging in treating the disease especially of severe respiratory illness which causes more severity. I entitled that this drug is very easy to collect and lesser economic in production.I concluded that this medicine will be a treasure for our Siddha system of medicine. It can be helpful in improving our Indian economy through this medicine, I hope this drug will be safe and promising drug for SARS-CoV2-COVID-19.

Recruitment & Eligibility

Inclusion Criteria

Rt-PCR positive patients, Asymptomatic patients, Fever, Dry cough, Sore throat, Difficulty in breathing.

Exclusion Criteria

Bronchogeniccarcinoma, Pulmonary TB, Pregnancy and lactating mothers, Status asthmatics.

Primary Outcome Measures

Name	Time	Method
Outcomes is mainly assessed by reduction in Clinical symptoms and Rt-PCR test Negative	3 Months

Secondary Outcome Measures

Name	Time	Method
Outcomes is mainly assessed by reduction in Clinical symptoms and Rt-PCR test Negative	The outcome is assessed by patients recovery progress with faster reductions in clinical symptoms and Rt-PCR test negative,also to avoid the mortality rate by administering Allopathy and Siddha medicines for the easy recovery and saftety measures in the treatment for SARS-CoV-2 and COVID-19.

Locations (1): Govt Kilpauk Medical College Hospital
🇮🇳
Chennai, TAMIL NADU, India
Govt Kilpauk Medical College Hospital
🇮🇳Chennai, TAMIL NADU, India
Dr P Vasanthamani
Principal investigator
9942064861
gkmcdean2018@gmail.com